Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00092534
First received: September 23, 2004
Last updated: August 28, 2014
Last verified: August 2014
Results First Received: July 20, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Conditions: Cervical Cancer
Genital Warts
Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Biological: Matching Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Quadrivalent Human Papillomavirus Vaccine (Group 1)

The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.

Placebo (Group 2)

The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.

Extension Study This group includes 581 subjects who received placebo during the base study, (Group 2-Base Study) and 13 additional subjects who were randomized to the active vaccine arm of the base study (from Group 1-Base Study), but received fewer than the full three doses of Quadrivalent HPV vaccine during the base study. Subjects designated as "Completed Period" are those who received three doses of Quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as "Not Completed" are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.

Participant Flow for 3 periods

Period 1:   Base Study Vaccination Period
    Quadrivalent Human Papillomavirus Vaccine (Group 1)     Placebo (Group 2)     Extension Study  
STARTED     6087     6080     0  
COMPLETED     5916     5954     0  
NOT COMPLETED     171     126     0  
Randomized not Vaccinated                 5                 5                 0  
Adverse Event                 3                 1                 0  
Death                 5                 4                 0  
Lost to Follow-up                 41                 37                 0  
Physician Decision                 1                 0                 0  
Pregnancy                 9                 7                 0  
Protocol Violation                 2                 1                 0  
Withdrawal by Subject                 85                 58                 0  
Moved                 14                 12                 0  
New Medical History (Not AEs)                 5                 0                 0  
Travel                 1                 0                 0  
Site Closed                 0                 1                 0  

Period 2:   Base Study Follow Up Period
    Quadrivalent Human Papillomavirus Vaccine (Group 1)     Placebo (Group 2)     Extension Study  
STARTED     5942 [1]   5971 [1]   0  
COMPLETED     5626     5277     0  
NOT COMPLETED     316     694     0  
Adverse Event                 2                 4                 0  
Death                 2                 1                 0  
Lost to Follow-up                 120                 146                 0  
Pregnancy                 6                 10                 0  
Protocol Violation                 1                 2                 0  
Withdrawal by Subject                 71                 62                 0  
Moved                 62                 58                 0  
Travel                 10                 7                 0  
Site Closed                 0                 2                 0  
Subjects continuing                 27                 31                 0  
Subjects in extension                 15                 371                 0  
[1] Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up.

Period 3:   Extension Study
    Quadrivalent Human Papillomavirus Vaccine (Group 1)     Placebo (Group 2)     Extension Study  
STARTED     0     0     594  
COMPLETED     0     0     449  
NOT COMPLETED     0     0     145  
Lost to Follow-up                 0                 0                 41  
Physician Decision                 0                 0                 1  
Pregnancy                 0                 0                 12  
Withdrawal by Subject                 0                 0                 18  
Moved                 0                 0                 6  
Travel                 0                 0                 2  
Site Closed                 0                 0                 21  
Study Ended                 0                 0                 29  
Protocol Deviation                 0                 0                 15  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Quadrivalent Human Papillomavirus Vaccine (Group 1)

The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.

Placebo (Group 2)

The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.

Total Total of all reporting groups

Baseline Measures
    Quadrivalent Human Papillomavirus Vaccine (Group 1)     Placebo (Group 2)     Total  
Number of Participants  
[units: participants]
  6087     6080     12167  
Age  
[units: years]
Mean ± Standard Deviation
  20.0  ± 2.2     19.9  ± 2.1     19.9  ± 2.1  
Age, Customized [1]
[units: participants]
     
Between 15 and 26 years     6087     6080     12167  
Gender  
[units: participants]
     
Female     6087     6080     12167  
Male     0     0     0  
Race/Ethnicity [2]
[units: participants]
     
Asian     151     135     286  
Black     171     227     398  
Hispanic American     555     557     1112  
Native American     1     1     2  
White     4584     4550     9134  
Other-Unspecified     625     610     1235  
[1] Age for study subjects was recorded at the time of subject entry into the base study.
[2] Subject race was determined at subject entry into the base study.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Tolerability; Incidence of the Composite Endpoint of HPV 16 or HPV 18 Related CIN2/3 or Invasive Cervical Carcinoma After Completion of the Vaccination Series for Relevant HPV Type   [ Time Frame: Follow-up through end of study (4 years) ]

2.  Secondary:   Subjects With Anti-HPV 6 Titer >/= 20 mMU/mL   [ Time Frame: Week 4 Postdose 3 (4 weeks after 3rd vaccine dose) ]

3.  Secondary:   Subjects With Anti-HPV 11 Titer >/= 16 mMU/mL   [ Time Frame: Week 4 Postdose 3 ]

4.  Secondary:   Subjects With Anti-HPV 16 Titer >/= 20 mMU/mL   [ Time Frame: Week 4 Postdose 3 ]

5.  Secondary:   Subjects With Anti-HPV 18 Titer >/= 24 mMU/mL   [ Time Frame: Week 4 Postdose 3 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information